

BEST AVAILABLE COPY



PCT/GB2004/002870



INVESTOR IN PEOPLE


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Stephen Handley

Dated

14 July 2004

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

The
Patent
Office

PATENT OFFICE

- 1 JUL 2003

LONDON

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road

Newport

Gwent NP9 1RH

1. Your reference

PA 534

02JUL03 E819483-1 C72481

P01/7700 0.00-0315450.7

2. Patent application number

(The Patent Office will fill in this part)

01 JUL 2003

0315450.7

3. Full name, address and postcode of the or of each applicant (underline all surnames)

08121485001

Patents ADP number (if you know it)

CELLTECH R+D LIMITED

208 BATH ROAD

SLOUGH, BERKSHIRE

SL1 3WE

If the applicant is a corporate body, give the country/state of its incorporation

UK

4. Title of the invention

BIOLOGICAL PRODUCTS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

CELLTECH R+D LIMITED

PATENTS DEPARTMENT

208 BATH ROAD

SLOUGH, BERKSHIRE

SL1 3WE

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

YES

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

0

Description

29

Claim(s)

3

Abstract

0

Drawing(s)

12 + 12 *Am.*

10. If you are also filing any of the following, state how many against each item.

Priority documents

0

Translations of priority documents

0

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

0

Request for preliminary examination and search (*Patents Form 9/77*)

0

Request for substantive examination (*Patents Form 10/77*)

0

Any other documents
(please specify)

0

11.

I/We request the grant of a patent on the basis of this application
FOR AND ON BEHALF OF CELLTECH R&D LIMITED

Signature

A.S. Blanchard

Date 01/07/03

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr. AMANDA BLANCHARD 01753 53465

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

BIOLOGICAL PRODUCTS

The present invention relates to improved antibody fragments and more specifically provides improved antibody fragments to which one or more effector molecules are attached and methods for their production.

The high specificity and affinity of antibody variable regions make them ideal diagnostic and therapeutic agents, particularly for modulating protein:protein interactions. Antibody fragments are proving to be versatile therapeutic agents, as seen by the recent success of products such as ReoPro®. The targeting function encoded in Fv, Fab, Fab', F(ab)₂ and other antibody fragments can be used directly or can be conjugated to one or more effector molecules such as cytotoxic drugs, toxins or polymer molecules to increase efficacy. For example, since these fragments lack an Fc region they have a short circulating half-life in animals but this can be improved by conjugation to certain types of polymer such as polyethylene glycol (PEG). Increasing the size of the conjugated PEG has been shown to increase the circulating half-life from minutes to many hours and modification of a Fab' with PEG ranging from 5kDa to 100kDa has been demonstrated (Chapman *et al.*, 1999, Nature Biotechnology, 17, 780-783; Leong *et al.*, 2001, Cytokine, 16, 106-119; Chapman, 2002, Advanced Drug Delivery Reviews, 54, 531-545). PEGylated antibody fragments such as CDP870 are currently undergoing clinical trials where the effect of the conjugated PEG is to bring the circulating half-life to acceptable levels for therapy.

Effector molecules may be attached to antibody fragments by a number of different methods, including through aldehyde sugars or more commonly through any available amino acid side-chain or terminal amino acid functional group located in the antibody fragment, for example any free amino, imino, thiol, hydroxyl or carboxyl group. The site of attachment of effector molecules can be either random or site specific.

Random attachment is often achieved through amino acids such as lysine and this results in effector molecules being attached at a number of sites throughout the antibody fragment depending on the position of the lysines. While this has been successful in some cases the exact location and number of effector molecules attached cannot be controlled and this can lead to loss of activity for example if too few are attached and/or loss of affinity if for example they interfere with the binding site (Chapman, 2002, *Advanced Drug Delivery Reviews*, 54, 531-545). As a result, controlled site specific attachment of effector molecules is usually the method of choice.

Site specific attachment of effector molecules is most commonly achieved by attachment to cysteine residues since such residues are relatively uncommon in antibody fragments. Antibody hinges are popular regions for site specific attachment since these contain cysteine residues and are remote from other regions of the antibody likely to be involved in antigen binding. Suitable hinges either occur naturally in the fragment or may be created using recombinant DNA techniques (See for example US 5,677,425; WO98/25971; Leong *et al.*, 2001 *Cytokine*, 16, 106-119; Chapman *et al.*, 1999 *Nature Biotechnology*, 17, 780-783). Alternatively site specific cysteines may be engineered into the antibody fragment for example to create surface exposed cysteine(s) (US 5,219,996).

Where effector molecules are to be site specifically attached via a cysteine, the target thiol in the antibody fragment is often capped by a small fermentation related peptide product such as glutathione or deliberately capped by a chemical additive used during antibody fragment extraction and purification such as 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB). These capping agents need to be removed to activate the target (hinge or surface) thiol. Antibody fragments have a native interchain disulphide bond between the heavy and light chain constant regions (C_H1 and C_L) that has generally been regarded as critical in maintaining the stability and binding properties of the antibody. As a result the activation of the target hinge or surface thiol must be carried out with some care such that the

inter C_L:C_H1 disulphide remains intact. Hence 'mild' reducing conditions are conventionally used to remove the thiol capping agent prior to reaction with the effector molecule. This is usually achieved by using thiol based reductants such as β-mercaptoethanol (β-ME), β-mercaptoethylamine (β-MA) and dithiothreitol (DTT). However, each of these reductants is known to be able to react with and stay attached to the cysteine which it is meant to reduce (Begg and Speicher 1999 Journal of Biomolecular techniques, 10,17-20) thereby reducing the efficiency of effector molecule attachment. Hence, following reduction and reaction with effector molecules, a large proportion of the antibody fragments do not have any effector molecules attached and these have to be purified away from the antibody fragments that have the correct number of effector molecules attached. This poor efficiency of modification is clearly a disadvantage during the large-scale production of modified therapeutic antibody fragments where it is important that maximum production efficiency is achieved.

The present invention provides a new class of modified antibody fragments that contain at least one effector molecule in which the heavy and light chains are not covalently linked. Despite the absence of any covalent linkage between the heavy and the light chain and the attachment of one or more effector molecules, the fragments of the invention perform comparably with wild type fragments in a number of *in vitro* and *in vivo* tests. Surprisingly these novel fragments have the same affinity for antigen and similar *in vivo* and *in vitro* stability as wild type fragments. A particular advantage of the fragments of the invention lies in their ease of manufacture and in particular, their efficiency of manufacture. The fragments thus provide a low cost alternative to currently available fragments having inter-chain covalent linkages.

Thus according to the present invention there is provided an antibody Fab or Fab' fragment to which at least one effector molecule is attached characterized in that the heavy chain in the fragment is not covalently bonded to the light chain

and both the interchain cysteine of C_L and the interchain cysteine of C_{H1} have been substituted with another amino acid.

5 The antibody fragment of the present invention may comprise any heavy chain and light chain pair having a variable (V_H/V_L) and constant region (C_H/C_L). The heavy and/or light chain constant region may be extended at its C-terminal with one or more amino acids. Particular examples include Fab and Fab' fragments.

The antibody fragment starting material for use in the present invention may be obtained from any whole antibody, especially a whole monoclonal antibody,
10 using any suitable enzymatic cleavage and/or digestion techniques, for example by treatment with pepsin. Alternatively, the antibody starting material may be prepared by the use of recombinant DNA techniques involving the manipulation and re-expression of DNA encoding antibody variable and/or constant regions. Standard molecular biology techniques may be used to modify, add or delete
15 amino acids or domains as desired. Any alterations to the variable or constant regions are still encompassed by the terms 'variable' and 'constant' regions as used herein.

The antibody fragment starting material may be obtained from any species including for example mouse, rat, rabbit, hamster camel, llama, goat or human.
20 Parts of the antibody fragment may be obtained from more than one species for example the antibody fragments may be chimeric. In one example the constant regions are from one species and the variable regions from another. The antibody fragment starting material may also be modified. In one example the variable region of the antibody fragment has been created using recombinant
25 DNA engineering techniques. Such engineered versions include those created for example from natural antibody variable regions by insertions, deletions or changes in or to the amino acid sequences of the natural antibodies. Particular examples of this type include those engineered variable region domains containing at least one CDR and optionally one or more framework amino acids
30 from one antibody and the remainder of the variable region domain from a second antibody. The methods for creating and manufacturing these antibody

fragments are well known in the art (see for example, Boss et al., US 4,816,397; Cabilly et al., US 6,331,415; Shrader et al., WO 92/02551; Ward et al., 1989, Nature, 341, 544; Orlandi et al., 1989, Proc.Natl.Acad.Sci. USA, 86, 3833; Riechmann et al., 1988, Nature, 322, 323; Bird et al, 1988, Science, 242, 423; Queen et al., US 5,585,089; Adair, WO91/09967; Mountain and Adair, 1992, Biotechnol. Genet. Eng. Rev, 10, 1-142; Verma et al., 1998, Journal of Immunological Methods, 216, 165-181).

Fab' fragments for use in the present invention are extended at the C-terminus of the heavy chain by one or more amino acids. Typically the Fab' fragments for use in the present invention possess a native or a modified hinge region. The native hinge region is the hinge region normally associated with the C_H1 domain of the antibody molecule. A modified hinge region is any hinge that differs in length and/or composition from the native hinge region. Such hinges can include hinge regions from any other species, such as human, mouse, rat, rabbit, hamster, camel, llama or goat hinge regions. Other modified hinge regions may comprise a complete hinge region derived from an antibody of a different class or subclass from that of the C_H1 domain. Thus, for instance, a C_H1 domain of class γ 1 may be attached to a hinge region of class γ 4. Alternatively, the modified hinge region may comprise part of a natural hinge or a repeating unit in which each unit in the repeat is derived from a natural hinge region. In a further alternative, the natural hinge region may be altered by converting one or more cysteine or other residues into neutral residues, such as alanine, or by converting suitably placed residues into cysteine residues. By such means the number of cysteine residues in the hinge region may be increased or decreased. In addition other characteristics of the hinge can be controlled, such as the distance of the hinge cysteine(s) from the light chain interchain cysteine, the distance between the cysteines of the hinge and the composition of other amino acids in the hinge that may affect properties of the hinge such as flexibility e.g. glycines may be incorporated into the hinge to increase rotational flexibility or prolines may be incorporated to reduce flexibility.

Alternatively combinations of charged or hydrophobic residues may be incorporated into the hinge to confer multimerisation properties. Other modified hinge regions may be entirely synthetic and may be designed to possess desired properties such as length, composition and flexibility.

5

A number of modified hinge regions have already been described for example, in US5,677,425, WO9915549, and WO9825971 and these are incorporated herein by reference. Typically hinge regions for use in the present invention will contain between 1 and 11 cysteines. Preferably between 1 and 4 cysteines and
10 more preferably 1 or 2 cysteines. Particularly useful hinges include a modified human γ 1 hinge in which only one cysteine is present, comprising the sequence DKTHTCPP or DKTHTCAA and those containing two cysteines comprising the sequence DKTHTCPPCPA or DKTHTCAACPA.

15 The term effector molecule as used herein includes, for example, antineoplastic agents, drugs, toxins (such as enzymatically active toxins of bacterial or plant origin and fragments thereof e.g. ricin and fragments thereof) biologically active proteins, for example enzymes, other antibody or antibody fragments, synthetic or naturally occurring polymers, nucleic acids and fragments thereof e.g. DNA,
20 RNA and fragments thereof, radionuclides, particularly radioiodide, radioisotopes, chelated metals, nanoparticles and reporter groups such as fluorescent compounds or compounds which may be detected by NMR or ESR spectroscopy.

25 Particular antineoplastic agents include cytotoxic and cytostatic agents for example alkylating agents, such as nitrogen mustards (e.g. chlorambucil, melphalan, mechlorethamine, cyclophosphamide, or uracil mustard) and derivatives thereof, triethylenephosphoramidate, triethylenethiophosphoramide, busulphan, or cisplatin; antimetabolites, such as methotrexate, fluorouracil,
30 floxuridine, cytarabine, mercaptopurine, thioguanine, fluoroacetic acid, or fluorocitric acid, antibiotics, such as bleomycins (e.g. bleomycin sulphate),

doxorubicin, daunorubicin, mitomycins (e.g. mitomycin C), actinomycins (e.g. dactinomycin) plicamycin, calicheamicin and derivatives thereof, or esperamicin and derivatives thereof; mitotic inhibitors, such as etoposide, vincristine or vinblastine and derivatives thereof; alkaloids such as ellipticine; polyols such as taxicin-I or taxicin-II; hormones, such as androgens (e.g. dromostanolone or testolactone), progestins (e.g. megestrol acetate or medroxyprogesterone acetate), estrogens (e.g. dimethylstilbestrol diphosphate, polyestradiol phosphate or estramustine phosphate) or antiestrogens (e.g. tamoxifen); anthraquinones, such as mitoxantrone, ureas, such as hydroxyurea; hydrazines, such as procarbazine; or imidazoles, such as dacarbazine.

Chelated metals include chelates of di- or tripositive metals having a coordination number from 2 to 8 inclusive. Particular examples of such metals include technetium (Tc), rhenium (Re), cobalt (Co), copper (Cu), gold (Au), silver (Ag), lead (Pb), bismuth (Bi), indium (In), gallium (Ga), yttrium (Y), terbium (Tb), gadolinium (Gd), and scandium (Sc). In general the metal is preferably a radionuclide. Particular radionuclides include ^{99m}Tc , ^{186}Re , ^{188}Re , ^{58}Co , ^{60}Co , ^{67}Cu , ^{195}Au , ^{199}Au , ^{110}Ag , ^{203}Pb , ^{206}Bi , ^{207}Bi , ^{111}In , ^{67}Ga , ^{68}Ga , ^{88}Y , ^{90}Y , ^{160}Tb , ^{153}Gd and ^{47}Sc .

The chelated metal may be for example one of the above types of metal chelated with any suitable polyadentate chelating agent, for example acyclic or cyclic polyamines, polyethers, (e.g. crown ethers and derivatives thereof); polyamides; porphyrins; and carbocyclic derivatives.

In general, the type of chelating agent will depend on the metal in use. One particularly useful group of chelating agents in conjugates according to the invention, however, are acyclic and cyclic polyamines, especially polyaminocarboxylic acids, for example diethylenetriaminepentaacetic acid and derivatives thereof, and macrocyclic amines, e.g. cyclic tri-aza and tetra-aza derivatives (for example as described in International Patent Specification No.

WO 92/22583); and polyamides, especially desferriox-amine and derivatives thereof.

Synthetic or naturally occurring polymers include, for example optionally
5 substituted straight or branched chain polyalkylene, polyalkenylene, or
polyoxyalkylene polymers or branched or unbranched polysaccharides, e.g. a
homo- or hetero- polysaccharide such as lactose, amylose, dextran or glycogen.

Particular optional substituents which may be present on the above-mentioned
10 synthetic polymers include one or more hydroxy, methyl or methoxy groups.
Particular examples of synthetic polymers include optionally substituted straight
or branched chain poly(ethyleneglycol), poly(propyleneglycol), poly(vinylalcohol)
or derivatives thereof, especially optionally substituted poly(ethyleneglycol) such
as methoxypoly(ethyleneglycol) or derivatives thereof.

15 "Derivatives" as used herein is intended to include reactive derivatives, for
example thiol-selective reactive groups such as an α -halocarboxylic acid or
ester, e.g. iodoacetamide, an imide, e.g. maleimide, a vinyl sulphone or
disulphide maleimides and the like. The reactive group may be linked directly or
20 through a linker segment to the polymer. It will be appreciated that the residue
of such a group will in some instances form part of the product as the linking
group between the antibody fragment and the polymer.

The size of each polymer molecule may be varied as desired, but will generally
25 be in an average molecular weight range from 500Da to 50,000Da, preferably
from 5,000 to 40,000Da and more preferably from 10,000 to 40,000Da and
20,000 to 40,000Da. The polymer size may in particular be selected on the
basis of the intended use of the product. Thus, for example, where the product
is intended to leave the circulation and penetrate tissue, for example for use in
30 the treatment of a tumor, it may be advantageous to use a small molecular
weight polymer, for example with a molecular weight of around 5,000Da. For

applications where the product remains in the circulation, it may be advantageous to use a higher molecular weight polymer, for example having a molecular weight in the range from 25,000Da to 40,000Da.

- 5 Particularly preferred polymers include a polyalkylene polymer, such as a poly(ethyleneglycol) or, especially, a methoxypoly(ethyleneglycol) or a derivative thereof, and especially with a molecular weight in the range from about 10,000Da to about 40,000Da.
- 10 The polymers of the present invention may be obtained commercially (for example from Nippon Oil and Fats;Nektar Therapeutics) or may be prepared from commercially available starting materials using conventional chemical procedures.
- 15 Effector molecules of the present invention may be attached using standard chemical or recombinant DNA procedures in which the protein is linked either directly or via a coupling agent to the effector molecule. Particular chemical procedures include for example those described in International Patent Specification numbers WO 93/06231, WO92/22583, WO90/09195,
- 20 WO89/01476, WO9915549 and WO03031581. Alternatively, where the effector molecule is a protein or polypeptide the linkage may be achieved using recombinant DNA procedures, for example as described in European Patent Specification No. 392745.
- 25 In one example the effector molecules of the present invention may be attached to the protein through any available amino acid side-chain or terminal amino acid functional group located in the antibody fragment, for example any free amino, imino, thiol, hydroxyl or carboxyl group. Such amino acids may occur naturally in the antibody fragment or may be engineered into the fragment using
- 30 recombinant DNA methods. See for example US 5,219,996. In a preferred aspect of the invention an effector molecule is covalently linked through a thiol

group of a cysteine residue located in the fragment. The covalent linkage will generally be a disulphide bond or, in particular, a sulphur-carbon bond. In one example where a thiol group is used as the point of attachment appropriately activated effector molecules, for example thiol selective derivatives such as maleimide and cysteine derivatives may be used.

In a preferred aspect of the present invention at least one of the effector molecules attached to the antibody fragment is a polymer molecule, preferably PEG or a derivative thereof. As regards attaching poly(ethyleneglycol) (PEG) moieties in general, reference is made to "Poly(ethyleneglycol) Chemistry, Biotechnical and Biomedical Applications", 1992, J.Milton Harris (ed), Plenum Press, New York; "Poly(ethyleneglycol) Chemistry and Biological Applications", 1997, J. Milton Harris and S.Zalipsky (eds), American Chemical Society, Washington DC and "Bioconjugation Protein Coupling Techniques for the Biomedical Sciences", 1998, M. Aslam and A. Dent, Grove Publishers, New York.

In one example of the present invention all the effector molecules attached to the fragment are PEG and each molecule is covalently linked via a maleimide group to one or more thiol groups in the antibody fragment. The PEG may be any straight or branched molecule. To attach branched PEG molecules, a lysine residue is preferably covalently linked to the maleimide group. To each of the amine groups on the lysine residue is preferably attached a methoxy(poly(ethyleneglycol) polymer. In one example the molecular weight of each polymer is approximately 20,000Da and the total molecular weight of the entire polymer molecule is therefore approximately 40,000Da.

The term interchain cysteine as used herein refers to a cysteine in the heavy or light chain constant region that would be disulphide linked to a cysteine in the corresponding heavy or light chain constant region in a naturally occurring antibody-molecule. In particular the interchain cysteines of the present

invention are a cysteine in the constant region of the light chain (C_L) and a cysteine in the first constant region of the heavy chain (C_{H1}) that are disulphide linked to each other in naturally occurring antibodies. Examples of such cysteines may typically be found at position 214 of the light chain and 233 of the heavy chain of human IgG1, as defined by Kabat *et al.*, 1987, in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA. It will be appreciated that the exact positions of these cysteines may vary from that of naturally occurring antibodies if any modifications, such as deletions, insertions and/or substitutions have been made to the antibody starting material.

In the modified fragments of the present invention the disulphide linkage between the interchain cysteine of C_L and the interchain cysteine of C_{H1} is absent. As a result the heavy chain in the antibody fragment is not covalently bonded to the light chain. In the present invention the interchain cysteines in the antibody fragment starting material have both been replaced by another amino acid, preferably an amino acid that does not contain a thiol group. By replace we mean that where the interchain cysteine would normally be found in the antibody fragment another amino acid is in its place. Examples of suitable amino acids include serine, threonine, alanine, glycine or any polar amino acid. A particularly preferred amino acid is serine. The amino acids used to replace the interchain cysteines may be the same in both chains or different from each other. The methods for replacing amino acids are well known in the art of molecular biology. Such methods include for example site directed mutagenesis using methods such as PCR to delete and/or substitute amino acids or *de novo* design of synthetic sequences.

In the present invention at least one effector molecule is attached to the antibody fragment. The effector molecules may be attached by any of the means described herein.

In one example of the present invention at least one effector molecule is attached to a cysteine residue in the antibody fragment constant region.

Additional effector molecules may be attached elsewhere in the antibody fragment, in particular the constant region and/or the hinge region using the

5 methods described herein. Suitable cysteines for attachment include naturally occurring cysteines and cysteines that have been engineered into the fragment using recombinant DNA techniques. In one example two cysteines are engineered into the antibody fragment, one in each of the heavy and light chain constant regions. In one particular example these cysteines are engineered at
10 positions whereby they can form a disulphide linkage with each other in the antibody starting material.

Particular fragments according to this aspect of the invention are those where:

- (i) at least one effector molecule is attached to the heavy or light chain
15 constant region or
- (ii) an effector molecule is attached to a cysteine in the light chain constant region and the heavy chain constant region or
- (i) the cysteine residues in the heavy and light chain constant regions which are attached to effector molecules would otherwise be linked to
20 each other via a disulphide bond if the effector molecules were not attached

In another example of the present invention the antibody fragment is a Fab' fragment and at least one effector molecule is attached to the fragment via the
25 hinge region, preferably via a cysteine present in the hinge region. Additional effector molecules may be attached elsewhere in the antibody fragment, in particular the constant region and/or the hinge region using the methods described herein.

30 Particular fragments according to this aspect of the invention are those where:

- ~~(i) one effector molecule is attached to the hinge region or~~

- (ii) two effector molecules are attached to the hinge region or
- (iii) all effector molecules attached to the fragment are attached to the hinge region

5 Also provided by the present invention are methods for attaching one or more effector molecules to the antibody Fab or Fab' fragments of the present invention, said method comprising:

- 10 i) Treating an antibody Fab or Fab' fragment in which the both the interchain cysteine of C_L and the interchain cysteine of C_H1 have been replaced with another amino acid with a reducing agent capable of generating at least one free thiol group in the fragment
- ii) Reacting the treated fragment with an effector molecule

15 The methods provided by the present invention enable one or more effector molecule(s) to be attached to cysteines in the antibody fragment, in particular to cysteines in the constant region and/or the hinge. Two or more effector molecules can be attached to the antibody fragment either simultaneously or sequentially by repeating the method.

20 The methods of the present invention also extend to one or more steps before and/or after the reduction method described above in which further effector molecules are attached to the antibody fragment using the methods described previously, for example via other available amino acids side chains such as
25 amino or imino groups.

The reducing agent for use in the methods of the present invention is any reducing agent capable of reducing cysteines in the antibody fragment starting material to produce free thiols. Preferably the reducing agent efficiently reduces
30 all available thiols. In one aspect of the present invention the reducing agent will need to be strong enough to reduce any disulphide bonds between the

cysteines of the heavy and light chain constant regions, for example cysteines that have been engineered into the constant region, in order to allow attachment of effector molecules to said cysteines. Where there are no interchain disulphide bonds, for example where there are no engineered pairs of cysteines in the constant regions and the interchain cysteines of C_L and C_H1 have been substituted with another amino acid, the reducing agent must be capable of efficiently liberating free thiols from the remaining cysteine(s) in the antibody fragment. As the antibody molecules of the present invention have no requirement for the interchain disulphide bond stronger reducing agents can be used than are conventionally used with wild type antibody fragments. As a result a higher number of free thiols are produced and a higher proportion of the antibody fragments are correctly modified. The antibody fragments of the present invention can therefore be produced more efficiently and cost effectively than conventional antibody fragments. It will be clear to a person skilled in the art that suitable reducing agents may be identified by determining the number of free thiols produced after the antibody fragment is treated with the reducing agent. Methods for determining the number of free thiols are well known in the art, see for example Lyons *et al.*, 1990, Protein Engineering, 3, 703. Reducing agents for use in the present invention are widely known in the art for example those described in Singh *et al.*, 1995, Methods in Enzymology, 251, 167-73. Particular examples include thiol based reducing agents such as reduced glutathione (GSH), β -mercaptoethanol (β -ME), β -mercaptoethylamine (β -MA) and dithiothreitol (DTT). Alternatively the antibody fragments of the present invention may be reduced using electrolytic methods, such as the method described in Leach *et al.*, 1965, Div. Protein. Chem, 4, 23-27 and using photoreduction methods, such as the method described in Ellison *et al.*, 2000, Biotechniques, 28 (2), 324-326. Preferably however, the reducing agent for use in the present invention is a non-thiol based reducing agent capable of liberating one or more thiols in an antibody fragment. Preferably the non-thiol based reducing agent is capable of liberating all available thiols in an antibody fragment. Preferred reducing agents for use in the present invention are

trialkylphosphine reducing agents (Ruegg UT and Fudinger, J., 1977, Methods in Enzymology, 47, 111-126; Burns J *et al.*, 1991, J.Org.Chem, 56, 2648-2650). Particular examples of which include tris(2-carboxyethyl)phosphine (TCEP), tris butyl phosphine (TBP), tris-(2-cyanoethyl) phosphine and tris-(2-hydroxyethyl) phosphine. Most preferably the reducing agent for use in the present invention is TCEP. It will be clear to a person skilled in the art that the concentration of reducing agent for use in the present invention can be determined empirically for example, by varying the concentration of reducing agent and measuring the number of free thiols produced. Typically the reducing agent for use in the present invention is used in excess over the antibody fragment for example between 2 and 1000 fold molar excess. Preferably the reducing agent is in 2, 3, 4, 5, 10, 100 or 1000 fold excess. In one preferred example the reducing agent is in 4 molar excess.

The modified antibody fragments according to one aspect of the invention may be prepared by reacting an antibody fragment containing at least one reactive cysteine residue with an effector molecule, preferably a thiol-selective activated effector molecule. The reaction may generally be performed in a solvent, for example an aqueous buffer solution such as acetate or phosphate, at around neutral pH, for example around pH 4.5 to around pH 8.0. The reaction may generally be performed at any suitable temperature, for example between about 5°C and about 70°C, for example at room temperature. The solvent may optionally contain EDTA at between 1 and 5mM, preferably 2mM. The effector molecule will generally be employed in excess concentration relative to the concentration of the antibody fragment. Typically the effector molecule is in between 2 and 100 fold molar excess, preferably 5, 10 or 50 fold excess.

Where necessary, the desired product containing the desired number of effector molecules may be separated from any other product generated during the production process and containing an unwanted number of effector molecules

by conventional means, for example by chromatography techniques such as ion exchange, size exclusion or hydrophobic interaction chromatography.

Also provided by the present invention is a mixture containing two or more
5 antibody Fab or Fab' fragments, characterized in that the mixture is enriched for Fab or Fab' fragments in which the light chain in said fragments is not covalently bonded to the heavy chain, both the interchain cysteines of C_L and C_{H1} have been replaced by another amino acid and at least one effector molecule is attached to the fragment. Said mixture may be produced using the methods
10 provided by the present invention. By 'enriched' we mean that the antibody fragment with the desired number of effector molecules attached accounts for 50% or greater of the mixture. Preferably the antibody fragment with the desired number of effector molecules attached accounts for between 50 and 99% of the mixture. Preferably the mixtures are enriched by greater than 50%,
15 preferably greater than 60%, more preferably greater than 70%. The proportion of such mixtures containing the antibody fragment with the desired number of effector molecules may be determined by using the size exclusion HPLC methods described herein. In one example the mixture is enriched with a Fab' fragment in which the light chain in said fragment is not covalently bonded to the
20 heavy chain, both the interchain cysteines of C_L and C_{H1} have been replaced by another amino acid and one effector molecule is attached to the hinge region. In another example the mixture is enriched with a Fab' fragment in which the light chain in said fragment is not covalently bonded to the heavy chain, both the interchain cysteines of C_L and C_{H1} have been replaced by another amino acid
25 and two effector molecules are attached to the hinge region.

Also provided by the present invention is a process which can be used to facilitate the isolation of soluble, correctly folded antibody fragments in which the light chain in said fragments is not covalently bonded to the heavy chain and
30 both the interchain cysteines of C_L and C_{H1} have been replaced by another amino acid. This aspect of the invention relates to the recombinant production

of said antibody fragments in a host cell and is particularly suited to antibody Fab or Fab' fragments which are expressed in bacterial cells transformed with a vector comprising DNA coding for said antibodies. High temperature heat extractions are commonly used in the extraction of conventional antibodies expressed in bacterial cells (see the methods described in US 5,665,866, incorporated herein by reference) in order to obtain correctly folded and assembled antibody fragments, free of host proteins and antibody-related material such as free heavy and light chains or fragments thereof.

Conventional antibody fragments containing an interchain disulphide linkage between the heavy and light chain constant regions are typically extracted at around 60 to 65°C. However, in one example of the present invention the Fab or Fab' fragment starting material does not have a covalent linkage between the heavy and light chains. Surprisingly we have been able to demonstrate that a heat extraction can still be used to obtain these antibody fragments despite the absence of the disulphide linkage. Hence the present invention also provides a process to facilitate the isolation of antibody Fab or Fab' fragments produced in bacterial cells in which the light chain in said fragments is not covalently bonded to the heavy chain and both the interchain cysteines of C_L and C_{H1} have been replaced by another amino acid, comprising subjecting a preparation comprising said antibody Fab or Fab' fragments to an elevated temperature within the range of 34 to 59°C and recovering said antibody Fab or Fab' fragments from said preparation. Preferably the temperature for use in the process is within the range 45 to 59°C, more preferably within the range 50 to 56°C. Preferred temperatures for use in the process are 50, 51, 52, 53, 54, 55 and 56°C.

The antibody fragments according to the invention may be useful in the detection or treatment of a number of diseases or disorders. Such diseases or disorders may include those described under the general heading of infectious disease, e.g. bacterial infection, fungal infection, inflammatory disease/autoimmunity e.g. rheumatoid arthritis, osteoarthritis, inflammatory bowel disease; cancer; allergic/atopic disease e.g. asthma, eczema; congenital

disease, e.g. cystic fibrosis, sickle cell anemia; dermatologic disease e.g. psoriasis; neurologic disease, e.g. multiple sclerosis; transplants e.g. organ transplant rejection, graft-versus-host disease; and metabolic/idiopathic disease e.g. diabetes.

5

The antibody fragments according to the invention may be formulated for use in therapy and/or diagnosis and according to a further aspect of the invention we provide a pharmaceutical composition comprising an antibody Fab or Fab' fragment to which at least one effector molecule is attached characterized in that
 10 the heavy chain in the fragment is not covalently bonded to the light chain and both the interchain cysteine of C_L and the interchain cysteine of C_H1 have been substituted with another amino acid, together with one or more pharmaceutically acceptable excipients, diluents or carriers.

15 **EXAMPLES**

The present invention will now be described by way of example only, in which reference is made to:

20 Figure 1: Proportions of mono-PEGylated vs. unPEGylated g165Fab' LC-S HC-S, hinge-CAA produced using various reductants, as determined by size exclusion HPLC.

Figure 2a: Non-reducing SDS-PAGE of purified g165 Fab' variants.

Figure 2b: Non-reducing SDS-PAGE of PEGylated g165 Fab' variants

25 Figure 3: Non-reducing SDS-PAGE of purified g165 Fab' LC-C HC-C, hinge-CAA and g165Fab' LC-S HC-S, hinge-CAA following overnight incubation at various temperatures in an *E.coli* periplasmic extract.

Figure 4: Non-reducing SDS-PAGE showing the cation exchange recovery of g165 Fab' LC-S HC-S hinge CAA following overnight periplasmic extraction in

30 Tris/EDTA at a range of temperatures.

Figure 5: Protein G recovery of g165 Fab' LC-S HC-S hinge-CAA following overnight periplasmic extraction in Tris/EDTA at a range of temperatures

Figure 6: Protein G recovery of g165 Fab' LC-S HC-S hinge CAA following successive 1 hour incubations at increasing temperatures in a Tris/EDTA

5 periplasmic extraction.

Figure 7: Pharmacokinetics of intravenously dosed ^{125}I labelled mono-PEGylated g8516 Fab' in rats

Figure 8: Pharmacokinetics of subcutaneously dosed ^{125}I labelled mono-PEGylated g8516 Fab' in rats

10 Figure 9: Pharmacokinetics of intravenously dosed ^{125}I labelled di-PEGylated g8516 Fab' in rats

Figure 10: Neutralisation of intravenously dosed antigen-induced IL-6 generation by intravenously dosed Fab'-PEG in mice

Figure 11: Neutralisation of intraperitoneal dosed antigen-induced neutrophil accumulation by intravenous pre-dosing of g8516 Fab'-PEG in mice.

Figure 12: Non-reducing SDS-PAGE of mono and di-PEGylated g8516 Fab'

Fab' nomenclature and General Methods

20 The Fab' molecules used in the following examples are g165 Fab' which binds to a human cell surface receptor and g8516 which binds to the human cytokine IL-1 β . The nomenclature for each fragment uses the single letter code C for cysteine and S for serine to denote the amino acid at the site of the inter-chain cysteine of C_L in the light chain (LC) and the site of the inter-chain cysteine of C_{H1} in the heavy chain (HC). For example, a normal Fab' is 'g165 Fab' LC-C HC-C, hinge-CAA' whereas the version in which both the interchain cysteines have been substituted with a serine so there is no inter chain disulphide between C_L and C_{H1} is 'g165 Fab' LC-S HC-S, hinge-CAA'. A similar Fab' with a full $\gamma 1$ middle hinge is noted as 'g165 Fab' LC-S HC-S, hinge-CPPCPA'. A list of

25

30 the plasmids used in the following examples are shown in Table 1.

Table 1. Plasmid and protein details.

Plasmid	Protein	Disulphide structure
PDPH147	g165 Fab' LC-C, HC-C, hinge-CAA	LC-GE HC-KS DKTHT AA
PDPH197	g165 Fab' LC-S, HC-S, hinge-CAA	LC-GE HC-KSSDKTHT AA
PDPH238	g8516 Fab' LC-C, HC-C, hinge CPPCPA	LC-GE HC-KS DKTHT PP PA
PDPH241	g8516 Fab' LC-S, HC-S, hinge-CAA	LC-GE HC-KSSDKTHT AA
PDPH242	g8516 Fab' LC-S, HC-S, hinge-CPPCPA	LC-GE HC-KTSDKTHT PP PA
PDPH243	g8516 Fab' LC-S, HC-S, hinge-CPSCPA	LC-GE HC-KTSDKTHT PS PA

5 Production of Fab'

PCR mutagenesis was used to change the interchain cysteines of C_L and C_H1 in the Fab' fragments to serines. Fab' molecules were produced in *E.coli* strain W3110 and purified using standard methods (Humphreys et al., 2002, Protein Expression and Purification, 26, 309-320).

Reduction and PEGylation of Fab' fragments.

All reductions and PEGylations were performed in 0.1M Phosphate pH6.0; 2mM EDTA. The concentration of Fab' and reductant were as stated in each example. In all cases reduction was done for 30 minutes at room temperature (~24°C), the proteins desalted on a PD-10 column (Pharmacia) and then mixed with 5 fold molar excess of PEG-maleimide over Fab'. The 40kDa PEG was from Nektar and 20 and 30kDa PEG was from Nippon Oil and Fats. PEGylated Fab' was separated from unpegylated Fab' by size exclusion HPLC on analytical Zorbax GF-450 and GF-250 columns in series. These were developed with a

30min isocratic gradient of 0.2M phosphate pH 7.0 + 10% ethanol at 1ml/min and Fab' detected using absorbance at 214nm and 280nm.

5 **Example 1: Creation of novel PEGylated Fab' fragments**

The antibody Fab' fragments g165Fab' LC-S HC-S, hinge CAA and g8516 Fab' LC-S HC-S, hinge CAA were produced by replacing the interchain cysteines of C_L and C_{H1} with serine by PCR mutagenesis. A single PEG fragment was
 10 attached to the hinge of each fragment by reducing the hinge cysteine and attaching PEG-maleimide to said cysteine. In the case of g165Fab' LC-S HC-S, hinge CAA a number of different reducing agents were tested at a 4 molar excess over the Fab' and these were the thiol based reductants reduced glutathione (GSH), β -mercaptoethanol (β -ME), β -mercaptoethylamine (β -MA)
 15 and dithiothreitol (DTT) and the non-thiol based reductant tris carboxyethyl phosphine (TCEP). Following reduction and PEGylation the number of PEG molecules attached to the Fab' fragments was determined by size exclusion chromatography.

20 Very high levels of mono-PEGylation were obtained when TCEP was used as the reductant and the ratio of PEGylated to unPEGylated material was approximately 75:25 (Figure 1). Under these conditions the ratios for the thiol based reductants were as follows, DTT 64:36, β -MA 50:50, β -MA 20:80 and GSH 25:75. TCEP was clearly the most efficient reducing agent tested,
 25 producing a 10% increase in PEGylated material over DTT. The lack of an interchain disulphide between C_L and C_{H1} enables stronger reducing agents to be used that would ordinarily reduce the interchain disulphide in a conventional Fab' fragment. In our hands PEGylation of the same antibody fragment but with the inter-chain disulphide intact (g165 Fab' LC-C HC-C, hinge-CAA), using the
 30 thiol based reductants typically resulted in a low efficiency of monoPEGylation, 55% for DTT, 52% β MA, 20% β ME and 22% GSH (See also our co-pending

application, PA535). The novel fragments of the present invention can therefore be produced more efficiently than conventional antibody fragments. TCEP is one example of a useful reducing agent for producing the antibody fragments of the present invention.

5

Figures 2a and 2b show that a single PEG molecule was attached to the fragment. Figure 2a shows the purified Fab' fragment g165 Fab' LC-S HC-S, hinge CAA where the single band in lane 2 represents both free heavy and light chain. Figure 2b shows the increase in mass of the heavy chain of g165 Fab' LC-S HC-S, hinge CAA (lane 2) following attachment of a single PEG molecule to the hinge (the highest molecular weight band in lane 2). The lower molecular weight band in lane 2 is free light chain.

10

TCEP was also used to efficiently diPEGylate the hinge of g165Fab' LC-S HC-S, hinge CPPCPA, g8516 Fab' LC-S HC-S, hinge CPPCPA and g8516 Fab' LC-S HC-S, hinge CPSCPA.

15

The following examples demonstrate that these new fragments have similar properties to conventional fragments that contain an interchain disulphide bond.

20

Example 2 Stability tests of Fab' lacking the inter C_L:C_H1 disulphide

Effect of temperature on purified Fab'

25

To compare the temperature stability of the Fab' molecules with and without the interchain disulphide during extraction, *E.coli* cells were spiked with purified Fab'. Purified g165 Fab LC-C HC-C, hinge-CAA or g165 Fab LC-S HC-S, hinge-CAA were made up to a final concentration of 2mg/ml Fab' in 100mM Tris.Cl pH7.4 10mM EDTA containing a suspension of plasmid free W3110 *E.*

30

coli at 30 OD₆₀₀/ml. 20µl aliquots were incubated in 500µl eppendorf tubes overnight-in-heating-blocks at room temperature, 37 °C, 45 °C, 50 °C, 55 °C, 60

°C and 65°C. After the incubation the tubes were centrifuged at 13000g for 1 minute to pellet precipitated proteins and cellular debris, 5µl samples were taken from the supernatant (soluble fraction) and separated using non-reducing SDS-PAGE before staining with Coomassie Blue (Figure 3). 165 Fab' LC-C HC-C hinge-CAA was stable at 65°C (lanes 1-7, major band at approx 50kDa) while 165 Fab' LC-S HC-S hinge-CAA was stable up until 60°C (lanes 8-13, upper band heavy chain dimers, lower band free heavy and light chain), after which protein levels were reduced (lane 14).

Since SDS-PAGE is denaturing there is no guarantee that the LC, HC and Fab' bands seen on a gel represent correctly folded protein. Hence tests were done to see if Fab' could bind normally to ion exchange and ProteinG column matrices following different temperature incubations. Fermentation cell pastes of 165 Fab' LC-S HC-S hinge-CAA were shaken in Tris / EDTA overnight at 30°C, 37°C, 47°C, 52°C, 56°C and 60°C then tested for Fab' recovery by binding to SP sepharose or Protein G. Figure 4 shows SDS-PAGE of flow through (lanes 3-8) and eluate (lanes 9-14) from SP sepharose and demonstrates that recovery of LC and HC are not affected by temperatures up to and including 56°C (lanes 9-13). At 60°C levels of Fab' recovered from the cation exchange column were reduced (lane 14). Similarly, the Fab' in these Tris / EDTA extracts were found to bind to Protein G even after incubation overnight at temperatures up to 52°C (Figure 5) suggesting that the external surface is correctly folded even after exposure to these elevated temperatures.

In order to try and pinpoint the critical temperature involved in successful recovery of Fab' from 165 Fab' LC-S HC-S hinge-CAA fermentation cell pastes an overnight extraction at 30°C was performed. A sample was taken out as a reference. Thereafter the extraction was incubated with shaking for one hour at progressively increasing temperatures (50°C, 53°C, 56°C, 59°C, 62°C, 65°C and 68°C). Analysis for binding to protein G in Figure 6 showed that 59°C was the upper cumulative temperature for tolerance at 1 hour for such Fab'.

These data show clearly that the non-covalent interaction between cKappa and Fd is very strong and that surprisingly heat extraction at between 50 and 59°C can still be used to prepare the antibody fragments of the present invention.

5

Effect of lack of inter C_L:C_H1 disulphide bond on the physical performance of Fab' and Fab-PEG.

i) Purification of Fab'

10

Fab' engineered to lack inter C_L:C_H1 disulphide bonds were purified using protein G or ion exchange in exactly the same manner as Fab' containing inter C_L:C_H1 disulphide bonds. Since these involved elution at pH 2.7 (protein G) or equilibration at pH 4.5 (ion exchange) the Fab' interaction between the HC and

15 LC was clearly stable.

ii) Antigen binding affinity *in vitro*.

g8156 Fab' with one or two PEG molecules attached to the hinge in the presence or absence of a covalent linkage between LC and HC were analysed for antigen affinity using surface plasmon resonance. Table 2 shows that neither the lack of inter C_L:C_H1 disulphide or presence of di-PEGylation materially affects the binding affinity.

25 Table 2. Antigen affinity of mono and di-PEGylated Fab' in vitro.

Fab'	PEG	KD (nM)
g8516 LC-C HC-C, hinge-CAA	1 x 40kDa	0.10
g8516 LC-S HC-S, hinge-CAA	1 x 40kDa	0.13
g8516 LC-C HC-C, hinge-CPPCPA	2 x 20kDa	0.10
g8516 LC-S HC-S, hinge-CPPCPA	2 x 20kDa	0.31

Example 3 Pharmacokinetics of Fab'-PEG in rats.

i) Circulating half life of Fab' PEGylated on the hinge

5 PEGylation in the hinge of Fab' followed by ^{125}I labelling and intravenous or sub cutaneous injection into rats enables analysis of the serum permanence of potential therapeutic Fab'. The circulating half life of non-PEGylated Fab' is very short ($t_{1/2\beta} \approx 30$ minutes) and that of free LC or HC is likely to be shorter still. ^{125}I labelling of proteins is random. Hence Fab' that are PEGylated only on the HC and lack inter $\text{C}_\text{L}:\text{C}_\text{H}1$ disulphide bonds will lose approximately half of the
10 injected ^{125}I blood borne radioactivity within a few hours if LC dissociates from HC *in vivo*.

300 μg of Fab'-PEG per animal group was ^{125}I -labelled using Bolton and Hunter reagent (Amersham) to a specific activity of 0.22 - 0.33 $\mu\text{Ci}/\mu\text{g}$.

15 Male Sprague Dawley rats of 220-250 g (Harlan) were injected *intra venously* or *sub cutaneously* with 20 μg ^{125}I -labelled Fab'-PEG variants whilst under Halothane anaesthesia ($n = 6$ per group). Serial arterial bleeds from the tail were taken at 0.5, 2, 4, 6, 24, 48, 72 and 144 hours post administration. Samples were counted using a COBRATM Autogamma counter (Canberra
20 Packard). Data were plotted and Area Under Curve were calculated using GraphPad Prism (GraphPad Software Incorporated) and is expressed as % injected dose.hour (% i.d/hr). The $t_{1/2\alpha}$ is defined by time points 0.5, 2, 4, and 6, whilst the $t_{1/2\beta}$ is defined by time points 24, 48, 72 and 144. The means and standard errors of means (SEM) of data for all six animals are shown in Table 3.

25

g8516 Fab' LC-S HC-S hinge-CAA and g8516 Fab' LC-C HC-C hinge-CAA were modified with a single hinge branched 40kDa PEG using TCEP as the reductant and subjected to such a pharmacokinetic analysis in rats.

30 In an experiment where the Fab' were injected *intra venously* the half lives and curve shapes of these two materials were essentially identical (Table 3 and

Figure 7) suggesting that the LC and HC remain partnered even up to 6 days after injection into the rat circulation.

Again, in an experiment where the Fab' were injected *sub cutaneously* and the radioactivity sampled from the blood, the lack of covalent interaction between LC and HC did not affect the circulating half life (Table 3 and Figure 8).

When the Fab' hinge is extended to include the middle hinge of a human $\gamma 1$ isotype antibody there are two cysteines available for attachment of PEG. The data for when the hinge was di-PEGylated with 2 x 20kDa linear PEG (Table 3 and Figure 9) show that the pharmacokinetics are very similar to that of the mono-PEGylated Fab' control. There is a slight difference in the curve shape for the di-PEGylated Fab' as opposed to the mono-PEGylated Fab' and hence as a result it is not possible to calculate an α phase half life for the di-PEGylated material. The half life of the di-PEG-Fab' is the same irrespective of whether the LC and HC are covalently associated or not.

Table 3. Pharmacokinetic analysis of Fab-PEG in rat model.

Fab	PEG	Admin.	$t \frac{1}{2} \alpha$ (h)	$T \frac{1}{2} \beta$ (h)	AUC (0- ∞) (%dose*h)
g8516 Fab' LC-C HC-C Hinge-CAA	1x40kDa (branched)	<i>i.v.</i>	4.76 ± 1.3	48 ± 2.8	4554 ± 268
g8516 Fab' LC-S HC-S Hinge-CAA	1x40kDa (branched)	<i>i.v.</i>	4.2 ± 1.0	51 ± 2.8	5307 ± 600
g8516 Fab' LC-C HC-C Hinge-CPPCPA	2x20kDa	<i>i.v.</i>	-	36 ± 1.9	4671 ± 538
g8516 Fab' LC-C HC-C hinge-CPPCPA	2x30kDa	<i>i.v.</i>	-	39 ± 3.6	6734 ± 1693
g8516 Fab' LC-S HC-S Hinge-CPPCPA	2x20kDa	<i>i.v.</i>	-	37 ± 3.9	5224 ± 748
g8516 Fab' LC-C HC-C Hinge-CAA	1x40kDa (branched)	<i>s.c.</i>	-	47 ± 6.5	2061 ± 375
g8516 Fab' LC-S HC-S Hinge-CAA	1x40kDa (branched)	<i>s.c.</i>	-	50 ± 1.9	2014 ± 313

Example 4 Mouse antigen binding efficacy models: *In vivo* efficacy in animal models.

5 Further evidence of the resilience of the interaction between LC and HC is found in the ability of Fab' lacking inter C_L:C_H1 disulphide bonds to neutralise antigen in mouse models. The human cytokine, IL-1 β , antigen for g8516 Fab' elicits biological responses from mice when injected *i.v.* (IL-6 production) or *i.p.* (neutrophil migration) and these can be blocked or inhibited by neutralising
10 g8516 Fab-PEG. Antibodies have 6 CDR's (3 on each polypeptide) that are normally involved in antigen binding. Hence administration of monoPEGylated forms of g8516 Fab' LC-S HC-S hinge-CAA and g8516 Fab' LC-C HC-C hinge-CAA may be expected to block these antigen driven events if the LC and HC remain associated together. Unpairing and subsequent loss from the circulation
15 of the non-PEGylated LC would be expected to result in loss of neutralisation ability.

i) *i.v.* dosed g8516 Fab'-PEG and *i.v.* dosed hIL-1 β .

At time t= -15 min; Male Balb/c mice (19.9g) mice injected intravenously (*i.v.*)
20 with test mAb at 1, 3 and 10mg/kg in 100 μ l PBS, or PBS vehicle alone (under halothane anaesthesia). At t= 0; mice injected *i.v.* with antigen (30 μ g/kg) in 100 μ l PBS vehicle, or PBS (alone under halothane anaesthesia). At t=90 min; cardiac puncture was performed and blood drawn into heparinised saline (100 U/ml heparin) (under halothane anaesthesia). Mice were then killed by cervical
25 dislocation.

Plasma was prepared from the sampled blood by centrifugation (14000 x g, 2 min, RT) and stored at -20°C prior to determination of IL-6 levels by ELISA. IL-6 ELISA was performed according to manufacturers instructions (BD Pharmingen
30 OPT-EIA mIL-6). Samples were diluted 1/16.

Figure 10 shows that g8516 Fab' LC-S HC-S hinge-CAA was equally efficacious as g8516 Fab' LC-C HC-C hinge-CAA in neutralising antigen when administered *i.v.* at all doses tested.

5 ii) ***i.v.* dosed g8516 Fab'-PEG and intraperitoneal dosed hIL-1 β .**

The *i.v.* pre-dosing of Fab-PEG was extended to 1, 3 and 7 days prior to *i.p.* administration of the antigen in a different efficacy model.

10 Male Balb/c mice (21g) were injected intravenously (*i.v.*) with a single dose (3 mg/kg in 100 μ l PBS) of g8516 Fab'LC-C HC-C hinge-CAA-40kDa PEG, g8516 Fab'LC-S HC-S hinge-CAA-40kDa PEG, or ghA33 Fab'LC-C HC-C hinge-CAA-40kDa PEG (irrelevant control), 1, 3 or 7 days prior to an *i.p.* injection of hIL-1 β (3 ng/kg in 100 μ l PBS vehicle). After 120 minutes, mice were killed by cervical
15 dislocation and peritoneal lavage was performed (3ml PBS + 0.25% BSA, 12mM HEPES). A total leukocyte count was performed using a Coulter Counter. For identification of neutrophils, 50 μ l peritoneal lavage fluid was stained with 1:300 dilution of anti-CD45-CyChrome mAb and 1:300 dilution of anti-GR-1-PE mAb (anti-Ly6G/Ly6C) for 20 minutes (4°C, in the dark). Leukocytes were washed
20 once in PBS (0.25% BSA, 12mM HEPES), resuspended in 300 μ l PBS (0.25% BSA, 12mM HEPES) and analysed by flow cytometry. Neutrophils were identified as CD45⁺GR-1^{HIGH}.

Figure 11 shows that there was no difference between g8516 Fab-PEG that
25 have, or lack inter C_L:C_H1 disulphide bonds at any of the time points. This demonstrates that efficacy is retained during 1 week in the mouse circulation and therefore by implication that LC and HC remain associated during this time. Non reducing SDS-PAGE of g8516 Fab-PEG material used in these animal models is shown in Figure 12. This figure demonstrates that the LC and HC
30 association is non-covalent for g8516 Fab' LC-S HC-S, hinge-CAA-PEG (lanes 3 and 4, higher molecular weight band is heavy chain-with-PEG-attached-to-the

hinge, lower molecular weight band is free light chain) compared to the covalent linkage observed in g8516 Fab' LC-C HC-C, hinge CAA (lanes 1 and 2 single high molecular weight band demonstrating covalent linkage).

- 5 From the above examples it can clearly be seen that the novel PEGylated molecules of the present invention can be produced more efficiently than PEGylated antibodies that contain an inter $C_L:C_H1$ disulphide bond. The examples also demonstrate that PEGylation of Fab' which lack the interchain disulphide bond has no adverse effects on the biological activity or stability of
- 10 the antibody Fab' making these useful therapeutic molecules which can be produced more efficiently than conventional Fab'.

CLAIMS

1. An antibody Fab or Fab' fragment to which at least one effector molecule is attached characterized in that the heavy chain in the fragment is not covalently bonded to the light chain and both the interchain cysteine of C_L and the interchain cysteine of C_H1 have been replaced with another amino acid.
 2. The antibody fragment of claim 1 wherein the interchain cysteine of C_L and the interchain cysteine of C_H1 have been replaced with a non-thiol containing amino acid.
 3. The antibody fragment of claim 2 wherein the interchain cysteine of C_L has been replaced with serine.
 4. The antibody fragment of claim 2 wherein the interchain cysteine of C_H1 has been replaced with serine.
 5. The antibody fragment of claim 2 wherein both the interchain cysteine of C_H1 and the interchain cysteine of C_L have been replaced with serine.
 6. The antibody fragment of claims 1-5 wherein the interchain cysteine of C_L is at position 214 of the light chain and the interchain cysteine of C_H1 is at position 233 of the heavy chain.
 7. The antibody fragment of claims 1-6 where at least one effector molecule is attached to the heavy or light chain constant region.
 8. The antibody fragment of claims 1-7, wherein an effector molecule is attached to a cysteine in the light chain constant region and a cysteine in the heavy chain constant region.
 9. The antibody fragment of claim 8, wherein the cysteine residues in the heavy and light chain constant regions which are attached to effector molecules would otherwise be linked to each other via a disulphide bond if the effector molecules were not attached.
 10. An antibody Fab' fragment according to claims 1-9 that contains a modified hinge region.
-

11. An antibody Fab' fragment according to claim 10 in which the modified hinge contains 1 cysteine residue.
12. The antibody fragment of claim 10 in which the modified hinge contains 2 cysteine residues.
- 5 13. An antibody Fab' fragment according to claims 1-12 where at least one effector molecule is attached to the hinge region.
14. An antibody Fab' fragment according to claim 13 in which two effector molecules are attached to the hinge region.
- 10 15. An antibody Fab' fragment according to claims 1-14 in which all the effector molecules attached to the fragment are attached to the hinge region.
16. A method of producing an antibody Fab or Fab' fragment according to claims 1-15 comprising:
- 15 a. treating an antibody Fab or Fab' fragment in which both the interchain cysteine of C_L and the interchain cysteine of C_{H1} have been replaced with another amino acid with a reducing agent capable of generating at least one free thiol group in the fragment
- b. reacting the treated fragment with an effector molecule
- 20 17. The method according to claim 16 in which the reductant is a non-thiol based reductant.
18. The method according to claim 17 in which the reductant is a trialkylphosphine.
19. The method according to claim 18 in which the trialkylphosphine reductant is tris(2-carboxyethyl)phosphine (TCEP)
- 25 20. A mixture containing two or more Fab or Fab' fragments, characterized in that the mixture is enriched for Fab or Fab' fragments in which the light chain in said fragments is not covalently bonded to the heavy chain, both the interchain cysteines of C_L and C_{H1} have been replaced by another amino acid and at least one effector molecule is attached to the fragment.
- 30 21. A mixture according to claim 20 in which greater than 50% of the mixture comprises a Fab or Fab' fragment in which the light chain in said

fragment is not covalently bonded to the heavy chain, both the interchain cysteines of C_L and C_H1 have been replaced by another amino acid and at least one effector molecule is attached to the fragment.

5 22. The antibody fragment of claims 1-21 wherein the effector molecule is PEG

23. A pharmaceutical composition comprising an antibody fragment according to any of the preceding claims, together with one or more pharmaceutically acceptable excipients, diluents or carriers.

Figure 1.






Figure 2.

2a. ProteinG purified Fab'



Non-reducing SDS-PAGE

2b. PEGylated Fab'




Non-reducing SDS-PAGE

2 Fab' LC-S HC-S, hinge-CAA 2/12
6 Fab' LC-S HC-S, hinge-SAA

3/12


Figure 3.



Non-reducing SDS-PAGE

4/12


Figure 4.



Non-reducing SDS-PAGE


5/12

Figure 5.




6/12

Figure 6.




7/12

Figure 7




8/12

Figure 8




9/12

Figure 9




10/12

Figure 10




11/12

Figure 11



12/12

Figure 12.



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.